Therapeutic Assessment Market Review and Pipeline Landscape for Lung Transplant Rejection H2 2016
No of Pages – 69 Publishing Date - November, 2016 Browse detailed TOC, Tables, Figures and Charts in Global Serial Device Server Consumption 2016 Market Research Report athttp://www.marketresearchhub.com/report/lung-transplant-rejection-pipeline-review-h22016-report.html A latest pipeline guide for pharmaceutical and healthcare disease by Global market direct’s has been launched and added to Market Research Hub’s vast portfolio of research reports. The report is titled as “Lung Transplant Rejection- Pipeline Review, H2 2016”.
This research study provides comprehensive data on the therapeutic development for lung transplant rejection along with the analysis based on various stages of development, drug profiles, route of administration (RoA), mechanism of action (MoA) and molecule type. Firstly, the report starts with the brief introduction to lung transplant. This transplant is an effective treatment for a disease that has destroyed most of the lungs’ function. It replaces an injured or diseased lung with a healthy one. For people with severe lung disease, a transplant can bring back easier breathing and also ensure a long life. However, lung transplant surgery has major risks and complications such as bleeding, infection, clots, and cardiovascular disorders.
Get A Sample Report
The two main complications which may arise after the transplant include: organ rejection and infection. Since the body recognizes the new lung as a foreign object, it will normally try to get rid of it or "reject" it. Some of the major symptoms of lung transplant rejections are:
Fever over 100°F (38°C) "Flu-like" symptoms: aches, headache, dizziness, nausea & vomiting. Chest congestion Dry cough Shortness of breath New pain or tenderness around the lung. Fatigue
Chronic rejection after lung transplantation is considerably more common than most other solid organ transplants. Since the body's ability to fight infection is decreased, transplant recipients are more disposed to infections. According to the report, Immunosuppressive drugs are administered simultaneously which prevent the body from attacking the organ via various immune responses, as a result it helps in blocking organ rejection and enabling a successful transplant. The guide is built using primary data and facts sourced from global markets direct proprietary records, company & university websites, clinical trial registries, SEC filings, conferences, investor presentations and featured press releases from university sites along with industry-specific third party sources. Additionally, various dynamic tracking methods ensure that the most recent developments are captured on a real time basis.
Companies involved in the therapeutics development are as follows:
Apeptico Forschung und Entwicklung GmbH Novartis AG Kamada Ltd. Dompe Farmaceutici S.p.A. Proteo, Inc. Quark Pharmaceuticals, Inc.
Furthermore, the guide also helps in identifying developing players in the market along with their portfolios. Apart from that, the report enhances the decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lung Transplant Rejection Overview 6 Therapeutics Development 7 Pipeline Products for Lung Transplant Rejection - Overview 7 Lung Transplant Rejection - Therapeutics under Development by Companies 8 Lung Transplant Rejection - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11
Get A Sample Report
Lung Transplant Rejection - Products under Development by Companies 12 Lung Transplant Rejection - Companies Involved in Therapeutics Development 13 Apeptico Forschung und Entwicklung GmbH 13 Dompe Farmaceutici S.p.A. 14 Kamada Ltd. 15
Novartis AG 16 Proteo, Inc. 17 Quark Pharmaceuticals, Inc. 18 Lung Transplant Rejection - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 alpha-1 proteinase inhibitor (human) - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 everolimus - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FX-06 - Drug Profile 44
Ask For Discount Product Description 44 Mechanism Of Action 44 R&D Progress 44 QPI-1024 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 QPLI-1 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 R-554 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 R-801 - Drug Profile 50 Product Description 50 Mechanism Of Action 50
R&D Progress 50 reparixin - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 solnatide - Drug Profile 55 Product Description 55 Mechanism Of Action 55 Report Details – Date of Publishing – Nov, 2016 No of Pages – 69 Single User License – $2000 Multiple User License – $4000
Buy Report Now!
About Market Research HUB : Market Research HUB is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments. Contact– 90 State Street, Albany, NY 12207, United States Toll Free : 866-997-4948 (US-Canada) Tel : +1-518-621-2074 Email : sales@marketresearchhub.com Website : http://www.marketresearchhub.com/